---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-022547"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:18:23.920988+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock reports FY2025 net loss $378M; BLA resubmission expected in 2026 after FDA reinspection

## Summary
- Net loss $377.9M for 2025 ($3.29 per share) vs $246.3M in 2024; no revenue; cash $367.6M at Dec 31.
- Apitegromab BLA resubmission planned for 2026 after successful FDA reinspection of Catalent Indiana facility.
- Secured up to $550M non-dilutive debt facility with Blue Owl Capital; $100M drawn to retire prior debt.
- EMA decision on apitegromab MAA expected mid-2026; European launch (starting Germany) in H2 2026.
- Phase 2 FORGE trial for FSHD on track for mid-2026; SRK-439 Phase 1 topline data expected H2 2026.

## SEC filing metadata
- accession: 0001104659-26-022547
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/0001104659-26-022547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-022547
- JSON: https://secwatch.observer/filing/0001104659-26-022547.json
- Plain text: https://secwatch.observer/filing/0001104659-26-022547.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.